Market Cap 5.50B P/E - EPS this Y -59.70% Ern Qtrly Grth -
Income -359.71M Forward P/E -10.70 EPS next Y 18.80% 50D Avg Chg -1.00%
Sales 250.65M PEG -0.27 EPS past 5Y - 200D Avg Chg 23.00%
Dividend N/A Price/Book 99.13 EPS next 5Y 35.40% 52W High Chg -13.00%
Recommedations 1.70 Quick Ratio 8.89 Shares Outstanding 86.49M 52W Low Chg 141.00%
Insider Own 20.37% ROA -19.97% Shares Float 61.56M Beta 1.49
Inst Own 82.94% ROE -231.58% Shares Shorted/Prior 6.23M/5.97M Price 63.64
Gross Margin -35.53% Profit Margin -143.51% Avg. Volume 881,301 Target Price 79.47
Oper. Margin -95.57% Earnings Date Aug 9 Volume 688,366 Change 0.62%
Apellis Pharmaceuticals, Inc. News
08/02/21 Did Business Growth Power Apellis Pharmaceuticals' (NASDAQ:APLS) Share Price Gain of 277%?
07/29/21 Why Apellis (APLS) Might Surprise This Earnings Season
07/29/21 Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
07/26/21 Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
07/07/21 Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
07/07/21 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/06/21 Apellis’ Pipeline Creating Attractive Entry Point, Analyst Says
07/02/21 Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
06/30/21 Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
06/28/21 Where Do Hedge Funds Stand On Apellis Pharmaceuticals, Inc. (APLS)?
06/23/21 Apellis Pharmaceuticals to Host R&D Day on June 30, 2021
06/09/21 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
06/03/21 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
05/26/21 Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
05/25/21 Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study
05/25/21 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
05/20/21 Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
05/19/21 Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
05/18/21 Company News for May 18, 2021

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.

APLS Chatroom

User Image cctranscripts Posted - 9 hours ago

Apellis Pharmaceuticals, Inc.'s CHIEF MEDICAL OFFICER just disposed of 250 shares https://www.conferencecalltranscripts.com/summary/?id=9723702 $APLS

User Image cctranscripts Posted - 9 hours ago

Apellis Pharmaceuticals, Inc.'s Vice President - Accounting just cashed-in 1,000 options https://www.conferencecalltranscripts.com/summary/?id=9723655 $APLS

User Image Newsfilter Posted - 9 hours ago

$APLS $15,997.50 of shares sold by Grossi Federico (CHIEF MEDICAL OFFICER), reported in a new form 4 filed with the SEC https://newsfilter.io/a/fc1823cd6e2fa1f61e7e08226894bcfc

User Image risenhoover Posted - 10 hours ago

Insider Federico Grossi reports selling 250 shares of $APLS for a total cost of $15,997.50 https://fintel.io/n/us/apls/grossi-federico?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image risenhoover Posted - 10 hours ago

Insider Nicole D Perry reports selling 1,000 shares of $APLS for a total cost of $63,990.00 https://fintel.io/n/us/apls/perry-nicole-d?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Newsfilter Posted - 10 hours ago

$APLS $60,230.00 of shares sold by Perry Nicole D (Vice President - Accounting), reported in a new form 4 filed with the SEC https://newsfilter.io/a/1598181c4552c15b2d6937adc6b2db8b

User Image quantcha Posted - 1 day ago

Covered Call Alert: APELLIS PHARMACEUTICALS INC. COMMON STOCK $APLS returning up to 36.33% through https://wp.me/p5bLGB-dRjN

User Image tickeron Posted - 2 days ago

Do you agree with the A.I. prediction? $APLS in Downtrend: Stochastic indicator leaves overbought zone. View odds for this and other indicators: https://srnk.us/go/2923257

User Image uspto Posted - 07/31/21

SYFOVRE is being trademarked by Apellis Pharmaceuticals, Inc. https://uspto.report/TM/90852938 #SYFOVRE $APLS

User Image uspto Posted - 07/31/21

MAPVIZO is processing as a trademark filing by Apellis Pharmaceuticals, Inc. https://uspto.report/TM/90852930 #MAPVIZO $APLS

User Image tickeron Posted - 07/31/21

How does this make you feel? $APLS's in Downtrend: Moving Average Convergence Divergence (MACD) Histogram crosses below signal line. View odds for this and other indicators: https://srnk.us/go/2918545

User Image geroscience Posted - 07/30/21

$LCTX $APLS $ISEE CEO Culley firing shots: "I know there's a competitor of ours who wants to own the complement pathway, and frankly they're welcome to it - it's an ancient pathway, I think it's time for a modern approach."

User Image T8SK1 Posted - 07/30/21

$APLS Tweet Trends Today's Change 32 % + https://t8sk.com/APLS

User Image OGTrades1 Posted - 07/29/21

$APLS Waiting for short signal on APLS

User Image Stonkmoon Posted - 07/29/21

$APLS 2021-07-29 07:00 ET Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results Apellis Pharmaceuticals, Inc. https://stonkmoon.com/news/APLS/a31c8ce54a0b4d87e37cbddd5389a4ab

User Image Newsfilter Posted - 07/29/21

$APLS Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results https://newsfilter.io/a/bcded59479cc5101afe168043854e344

User Image BioWreck Posted - 07/29/21

$APLS Just treading water waiting for Earning Thursday afternoon.

User Image ChartMill Posted - 07/28/21

$DDS, $JYNT and $APLS are showing a squeeze play pattern today. They could be ready for breakout. https://www.chartmill.com/stock/stock-screener?sid=12&f=sqds,v1_50b300,sl_ti_105_X,exch_us&v=3&timeframe=DAILY&type=CANDLES&months=0.05&width=400&cl=F&o1=0&o2=57&op1=14&op2=20,1.5,10&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_Momentum_Squeeze_Play_Setups&utm_campaign=social_tracking

User Image BioWreck Posted - 07/28/21

$APLS Closed at $65.59, just two cents below support at $65.61 and just two cents above the 20-DMA. Volume's drying up, and Sentiment is slowly expanding to the downside. It wants to go lower heading into Earnings Thursday afternoon. Can it get down to $61 or so? Yep, but the Fed Head Powell's News Conference Wednesday could complicate things.

User Image T8SK1 Posted - 07/26/21

$APLS Tweet Trends Today's Change 32 % + https://t8sk.com/APLS

User Image Last10K Posted - 07/26/21

$APLS just filed with the SEC a Financial Exhibit https://last10k.com/sec-filings/apls/0001193125-21-223659.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=apls

User Image cctranscripts Posted - 07/26/21

Apellis Pharmaceuticals: Apellis Announces Closing Of Previously Announced Exchanges Of Approxi https://www.conferencecalltranscripts.com/summary/?id=9687064 $APLS

User Image Quantisnow Posted - 07/26/21

$APLS 📜 Apellis Pharmaceuticals, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits https://quantisnow.com/insight/1488014?s=s

User Image risenhoover Posted - 07/26/21

$APLS / Apellis Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 Apellis Pharmaceuti https://fintel.io/sf/us/apls?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Newsfilter Posted - 07/26/21

$APLS Form 8-K: On July 23, 2021, Apellis Pharmaceuticals closed its previously announced privately negotiated exchange with certain holders of its 3.500% Convertible Senior Notes due 2026. In the Exc.. https://newsfilter.io/a/b5d84b0aee8e63e9ecb3b6eade2d148c

User Image STCKPRO Posted - 07/26/21

$APLS NEW ARTICLE : Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock https://www.stck.pro/news/APLS/14567799

User Image cctranscripts Posted - 07/26/21

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500Convertible Senior Notes Due 2026 for Common Stock https://conferencecalltranscripts.com/summary/?id=259224&pr=true $APLS

User Image fla Posted - 07/26/21

$APLS [15s. delayed]: Issued Press Release on July 26, 07:00:00: Apellis Announces Closing of Previously Announced Exchanges of Approximat https://s.flashalert.me/wSJH0

User Image Stonkmoon Posted - 07/26/21

$APLS 2021-07-26 07:00 ET Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock Apellis Pharmaceuticals, Inc. https://stonkmoon.com/news/APLS/7cc71df6dd8a93926e76741bebaba0ca

User Image Quantisnow Posted - 07/26/21

$APLS 📰 Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock https://quantisnow.com/insight/1487409?s=s

Analyst Ratings
BMO Capital Outperform Jul 8, 21
JP Morgan Overweight Jul 2, 21
Needham Buy Jun 28, 21
UBS Buy May 21, 21
Credit Suisse Neutral Apr 29, 21
Goldman Sachs Buy Apr 16, 21
Credit Suisse Neutral Feb 26, 21
Credit Suisse Neutral Jan 29, 21
Raymond James Strong Buy Jan 8, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own
DeLong Mark Jeffrey Senior Vice P.. Senior Vice President Jul 16, 6:40 PM Option 15.52 1,000 15,520 10,490
Deschatelets Pascal Chief Scienti.. Chief Scientific Officer Jun 25, 9:48 PM Option 2.67 6,250 16,688 875,837
Deschatelets Pascal Chief Scienti.. Chief Scientific Officer Jun 25, 9:48 PM Sell 65.61 6,250 410,062 869,587
DeLong Mark Jeffrey Senior Vice P.. Senior Vice President May 19, 4:04 PM Option 15.52 2,000 31,040 11,490
Machiels Alec Director Director Apr 22, 6:17 PM Option 2.67 2,500 6,675 672,044
Deschatelets Pascal Chief Scienti.. Chief Scientific Officer Mar 11, 4:08 PM Option 2.67 6,250 16,688 871,337
Deschatelets Pascal Chief Scienti.. Chief Scientific Officer Mar 11, 4:08 PM Sell 50.74 6,250 317,125 865,087
Grossi Federico CHIEF MEDICAL.. CHIEF MEDICAL OFFICER Mar 8, 4:32 PM Option 3.2 5,000 16,000 62,814
Grossi Federico CHIEF MEDICAL.. CHIEF MEDICAL OFFICER Mar 8, 4:32 PM Sell 48.62 5,000 243,100 57,814
Watson David O. General Couns.. General Counsel Dec 15, 4:03 PM Option 13.85 18,333 253,912 51,802
Watson David O. General Couns.. General Counsel Dec 15, 4:03 PM Sell 52.77 18,333 967,432 43,404
Perry Nicole D Vice Presiden.. Vice President - Accounting Dec 8, 7:32 PM Option 3.76 18,000 67,680 18,000
Perry Nicole D Vice Presiden.. Vice President - Accounting Dec 8, 7:32 PM Sell 50 18,000 900,000
Dunlop A. Sinclair Director Director Dec 7, 6:58 PM Sell 50.63 25,000 1,265,750 199,728
Machiels Alec Director Director Nov 17, 7:12 PM Option 2.67 2,500 6,675 672,044
Machiels Alec Director Director Nov 17, 7:12 PM Sell 39.38 2,500 98,450 669,544
Machiels Alec Director Director Oct 16, 5:56 PM Option 2.67 2,500 6,675 672,044
Machiels Alec Director Director Oct 16, 5:56 PM Sell 35 2,500 87,500 669,544